PortfolioPlus
Portfolio-Tracker – Kurse, Renditeanalyse und Dividendenplaner an einem Ort.
Anzeige
Lixte Forum: Community User: DeRitter
Kommentare 147
DeRitter,
04.05.2021 17:15 Uhr
0
In dem Markt? Eine der wenigen grünen Positionen heute
Tennis123,
04.05.2021 14:03 Uhr
0
Könnte mal steigen
DeRitter,
29.04.2021 9:17 Uhr
0
Willkommen im Klub 🤞🏻
Tennis123,
29.04.2021 9:10 Uhr
0
Mal sehen ob was kommt bezüglich Krebs
Tennis123,
29.04.2021 9:10 Uhr
1
Auch drin
van_haze78,
28.04.2021 22:36 Uhr
0
Schauen wir wo die Reise hingeht 💪
DeRitter,
28.04.2021 21:52 Uhr
0
Wir heben ab
DeRitter,
17.03.2021 14:54 Uhr
1
LIXT PR
"EAST SETAUKET, NY, March 17, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, will participate in the virtual Benzinga Biotech Small Cap Conference being held March 24-25, 2021. Lixte Founder and Chief Executive Officer John S. Kovach, M.D., will present on Wednesday, March 24 at 10:55 a.m. ET in Track 1. Investors may register for the conference at the event website.
During the corporate presentation and in one-on-one investor meetings, Dr. Kovach will discuss Lixte's product pipeline of ongoing studies and planned trials of its lead clinical candidate LB-100, a unique first-in-class anti-cancer agent with no competitors known to Lixte currently in the clinic.
Dr. Kovach commented, "More than 40 preclinical studies with leading medical centers indicated that LB-100 enhances standard therapies for many cancers. We now have a number of exciting clinical investigations underway for LB-100, including three clinical trials and one pharmacology study. Our initial cancer targets are myelodysplastic syndrome, soft tissue sarcomas, small cell lung cancer, and glioblastoma.""
TheOneDay,
15.03.2021 12:47 Uhr
0
Pump and Dump 😂👍
DeRitter,
15.03.2021 9:03 Uhr
0
👍👍
MS85,
13.03.2021 16:19 Uhr
0
🤗
DeRitter,
12.03.2021 23:36 Uhr
0
To be presented - Anti-Cancer Therapy Enhancer LB-100 at the Virtual 33rd Annual ROTH Capital Conference
LB-100 is Currently in Clinical Studies for Four Cancer Targets:
◦ Phase 1b/2 for Myelodysplastic (MDS) Syndromes
◦ Phase 1b/2 for Advanced Soft Tissue Sarcoma
◦ Phase 0 (Pharmacodynamics) for Glioblastoma Multiforme
◦ Phase 1b for Small Cell Lung Cancer
◦ Pre-clinical for Angelman Syndrome
WALL.E,
12.03.2021 22:15 Uhr
0
👋
D
Drexxtor,
12.03.2021 22:04 Uhr
0
🧐🧐🧐
DeRitter,
12.03.2021 22:04 Uhr
0
🐥🐥🐥
WALL.E,
12.03.2021 22:01 Uhr
0
😉
Meistdiskutiert
|
|
Thema | ||
|---|---|---|---|
| 1 | Gorilla | -2,30 % | |
| 2 | Micron Neu | +3,53 % | |
| 3 | Lithium | -10,00 % | |
| 4 | RIM - RESEARCH IN MOTION Hauptdiskussion | +1,83 % | |
| 5 | Phunware 2025 | +1,44 % | |
| 6 | OCCIDENTAL PETROLEUM Hauptdiskussion | -2,97 % | |
| 7 | Atyr Pharma | +10,03 % | |
| 8 | TUI Hauptforum | +1,28 % | |
| 9 | ADIDAS Hauptdiskussion | -1,06 % | |
| 10 | Super Micro Computer Hauptdiskussion | +10,20 % | Alle Diskussionen |
Aktien
|
|
Thema | ||
|---|---|---|---|
| 1 | Gorilla | -2,30 % | |
| 2 | Micron Neu | +3,53 % | |
| 3 | Lithium | -10,00 % | |
| 4 | RIM - RESEARCH IN MOTION Hauptdiskussion | +1,83 % | |
| 5 | Phunware 2025 | +1,44 % | |
| 6 | OCCIDENTAL PETROLEUM Hauptdiskussion | -2,97 % | |
| 7 | Atyr Pharma | +10,03 % | |
| 8 | TUI Hauptforum | +1,28 % | |
| 9 | ADIDAS Hauptdiskussion | -1,06 % | |
| 10 | Super Micro Computer Hauptdiskussion | +10,20 % | Alle Diskussionen |